Market Intelligence, Clinical Progress, and High-Purity Reagents for B-Cell Malignancy Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CD79A drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD79A ECD-Fc / Heterodimer Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View CD79A Products |
| Gene Delivery | CD79A Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View CD79A Products |
| Benchmark Ab | Anti-CD79A (Sequence of Clinical Leads) Recombinant positive control. |
View CD79A Products |
| Validator | CD79A siRNA Set For knockdown verification. |
View CD79A Products |
| Related Target A | CD79B Obligate heterodimer partner; critical for BCR assembly and signaling. |
View CD79B Products |
| Related Target B | CD19 Synergistic B-cell co-receptor; highly relevant for combination therapies. |
View CD19 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native Heterodimer Conformation | Co-expressed CD79A/CD79B heterodimer proteins strictly verified by mass spectrometry. |
| Rapid Internalization Screening | HEK293 expressed (native glycosylation) ECD-Fc fusion proteins for optimal antibody-drug conjugate (ADC) uptake assays. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live CD79A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD79A therapeutics is intensifying, with major players shifting focus from traditional mAbs to antibody-drug conjugates (ADCs) and bispecific antibodies (BsAbs). As first-generation therapies reach the clinic, the next wave of R&D is targeting CD19/CD20-resistant B-cell malignancies by leveraging CD79A as a highly specific, rapidly internalizing alternative B-cell lineage marker.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Genentech, ADC Therapeutics | B-cell Lymphomas, DLBCL | Internalization Assay (Need high-purity ECD-Fc) |
| Bispecific (CD3 x CD79A) | Roche, Regeneron | Non-Hodgkin Lymphoma, CLL | Heterodimer Validation (Need Cross-reactive Abs) |
| CAR-T / Cell Therapy | Academic Institutions, Biotech Startups | Relapsed/Refractory B-ALL | Selectivity Assay (Need Lentivirus for Stable Cell Line) |